Velpatasvir + Sofosbuvir
Form: Tablet
Strength: Sofosbuvir - 400 mg + Velpatasvir - 100 mg
Reference Brands: Epclusa(US & EU)
Category: Anti Viral
Epclusa is a once-daily, fixed-dose combination of Sofosbuvir 400 mg and Velpatasvir 100 mg, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across all six genotypes. This pan-genotypic regimen offers a high sustained virologic response (SVR) rate of over 95%, making it a preferred choice for both treatment-naïve and previously treated patients. Epclusa is suitable for use with or without ribavirin, depending on liver disease status. Its simplified, one-pill-daily format improves adherence and outcomes. It is also available for pediatric patients aged 3 years and older in tablet and granule forms.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Zanamivir
Strength: 5 mg/blister
Form: Inhalation powder
Reference Brands: Relenza(EU & US)
View Details
Oseltamivir Phosphate Capsule
Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)
Form: Capsules and Oral solution
Reference Brands: Tamiflu(EU & US)
View Details
Amantadine
Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg
Form: Tablet; Capsule; Oral Solution and ER Capsule
Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)
View Details
Glecaprevir + Pibrentasvir
Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg
Form: Tablet
Reference Brands: Mavyret (US); Maviret (EU)
View Details